Nefrocarnit® (Levocarnitine)

• Nefrocarnit® is used to address disorders of carnitine metabolism and related energy‑deficient states.
• Primary carnitine deficiency: restores intracellular carnitine levels to improve fatty‑acid oxidation and reduce metabolic decompensation.
• Secondary carnitine deficiency: replenishes depleted carnitine pools, aiding recovery in patients with renal loss or prolonged dialysis.
• Metabolic disorders requiring carnitine supplementation: supports mitochondrial function in inherited or acquired conditions where fatty‑acid utilization is compromised.

• Levocarnitine acts as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle. By forming acyl‑carnitine esters, it enables β‑oxidation of fatty acids, thereby generating acetyl‑CoA for the citric acid cycle and supporting cellular ATP production, especially in tissues with high energy demand.

Adverse reactions may occur with intravenous levocarnitine administration.

Common Side Effects

• Nausea or vomiting
• Abdominal cramps or diarrhea
• Headache or dizziness
• Metallic taste in the mouth
• Flushing or warmth sensation
• Mild hypotension during infusion

Serious or Rare Side Effects

• Anaphylactic or severe allergic reaction
• Cardiac arrhythmia or tachycardia
• Severe hypotension or shock
• Muscle weakness or rhabdomyolysis
• Elevated serum ammonia levels

• When using Nefrocarnit®, clinicians should observe several safety measures.
• Monitor plasma carnitine levels: adjust dosing based on laboratory results.
• Assess renal function: dose may need modification in impaired clearance.
• Observe for infusion reactions: pause infusion if severe symptoms develop.
• Avoid concurrent use with known hypersensitivity to levocarnitine.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levocarnitine may interact with certain medications and clinical situations.

Major Interactions (Avoid)

• Valproic acid: increased risk of hyperammonemia.
• Hemodialysis: significant removal of drug, reducing therapeutic effect.
• Mitochondrial toxins (e.g., certain antiretrovirals): may exacerbate mitochondrial dysfunction.

Moderate Interactions (Monitor Closely)

• Carbapenem antibiotics: may lower plasma carnitine concentrations.
• Other nutritional supplements (e.g., CoQ10, riboflavin): monitor for additive metabolic effects.